Trial reportJournal of clinical hypertension (Greenwich, Conn.)2005
Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta-analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2022Pooled it
- Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.Journal of hypertension · 2011Trial
- Should two-drug initial therapy for hypertension be recommended for all patients?Current hypertension reports · 2012Review
- Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence.Patient preference and adherence · 2012Article
- Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: a randomized, double blind, multicenter study.BMC research notes · 2011Article
- Prevalence of uncontrolled hypertension in primary care settings in Al seeb wilayat, oman.Sultan Qaboos University medical journal · 2011Article
- Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system.Journal of human hypertension · 2009Review
- Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.Vascular health and risk management · 2009Review
- Control and management of hypertension at a university health centre in oman.Sultan Qaboos University medical journal · 2008Article
- Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk.International journal of clinical practice · 2008Review
- Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination.Vascular health and risk management · 2008Review
- Prompt, aggressive BP lowering in high-risk patients.Journal of clinical hypertension (Greenwich, Conn.) · 2008Review
- Hypertension control in the elderly.Journal of clinical hypertension (Greenwich, Conn.) · 2008Review
- Risk-based classification of hypertension and the role of combination therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2008Review
- Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.Journal of human hypertension · 2007Review
- More medications, fewer pills: combination medications for the treatment of hypertension.The Canadian journal of cardiology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systolic hypertension is predominant among patients over 50 years of age, is a more important cardiovascular risk factor than diastolic blood pressure, and is more difficult to control than diastolic blood pressure. Consequently, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommends combination therapy as first-line treatment for patients with stage 2 hypertension. In the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study, 24-hour ambulatory blood pressure monitoring was used to identify patients with systolic hypertension and to determine the impact of 8 weeks of treatment with either amlodipine besylate/benazepril HCl 5/20 mg combination therapy (n=149), amlodipine besylate 5 mg (n=146), or benazepril HCl 20 mg (n=148). Combination therapy was significantly more effective in reducing systolic blood pressure and pulse pressure than either monotherapy (p<0.0001). Significantly greater percentages of patients in the combination group compared with either monotherapy achieved blood pressure control (p<0.0001). Adverse events were low in all three treatment arms, with less peripheral edema in the combination group than in the amlodipine-treated group. The combination of amlodipine besylate/benazepril HCl given to patients with stage 2 systolic hypertension resulted in significantly greater reductions in blood pressure and pulse pressure than those seen with monotherapy and was at least as well tolerated as the separate components. This data supports the recommendation of the JNC 7 for the use of combination therapy in patients with stage 2 hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.